Ingevity Past Earnings Performance
Past criteria checks 0/6
Ingevity's earnings have been declining at an average annual rate of -45%, while the Chemicals industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 6.9% per year.
Key information
-45.0%
Earnings growth rate
-44.9%
EPS growth rate
| Chemicals Industry Growth | 12.4% |
| Revenue growth rate | 6.9% |
| Return on equity | -262.8% |
| Net Margin | -38.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ingevity makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,479 | -564 | 171 | 28 |
| 30 Jun 24 | 1,548 | -431 | 172 | 29 |
| 31 Mar 24 | 1,640 | -112 | 183 | 30 |
| 31 Dec 23 | 1,692 | -5 | 184 | 32 |
| 30 Sep 23 | 1,704 | 127 | 196 | 32 |
| 30 Jun 23 | 1,740 | 177 | 210 | 32 |
| 31 Mar 23 | 1,678 | 202 | 207 | 32 |
| 31 Dec 22 | 1,668 | 212 | 198 | 30 |
| 30 Sep 22 | 1,621 | 225 | 191 | 30 |
| 30 Jun 22 | 1,516 | 146 | 181 | 29 |
| 31 Mar 22 | 1,454 | 130 | 179 | 27 |
| 31 Dec 21 | 1,392 | 118 | 179 | 26 |
| 30 Sep 21 | 1,381 | 135 | 169 | 25 |
| 30 Jun 21 | 1,336 | 209 | 160 | 24 |
| 31 Mar 21 | 1,248 | 185 | 151 | 23 |
| 31 Dec 20 | 1,216 | 181 | 150 | 23 |
| 30 Sep 20 | 1,194 | 180 | 153 | 22 |
| 30 Jun 20 | 1,222 | 170 | 159 | 21 |
| 31 Mar 20 | 1,304 | 206 | 163 | 21 |
| 31 Dec 19 | 1,293 | 184 | 163 | 20 |
| 30 Sep 19 | 1,268 | 182 | 158 | 20 |
| 30 Jun 19 | 1,219 | 171 | 152 | 21 |
| 31 Mar 19 | 1,175 | 161 | 145 | 22 |
| 31 Dec 18 | 1,134 | 169 | 133 | 22 |
| 30 Sep 18 | 1,085 | 169 | 125 | 22 |
| 30 Jun 18 | 1,037 | 153 | 116 | 21 |
| 31 Mar 18 | 989 | 138 | 107 | 20 |
| 31 Dec 17 | 972 | 127 | 107 | 20 |
| 30 Sep 17 | 954 | 94 | 104 | 19 |
| 30 Jun 17 | 942 | 53 | 103 | 18 |
| 31 Mar 17 | 927 | 45 | 100 | 18 |
| 31 Dec 16 | 908 | 35 | 96 | 18 |
| 30 Sep 16 | 898 | 34 | 93 | 13 |
| 30 Jun 16 | 902 | 64 | 95 | 9 |
| 31 Mar 16 | 919 | 66 | 105 | 5 |
| 31 Dec 15 | 958 | 80 | 93 | 17 |
| 30 Sep 15 | 999 | 99 | 107 | 8 |
| 30 Jun 15 | 1,025 | 115 | 108 | 8 |
| 31 Mar 15 | 1,022 | 121 | 104 | 8 |
| 31 Dec 14 | 1,036 | 129 | 108 | 0 |
| 31 Dec 13 | 980 | 119 | 92 | 11 |
Quality Earnings: IGX is currently unprofitable.
Growing Profit Margin: IGX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IGX is unprofitable, and losses have increased over the past 5 years at a rate of 45% per year.
Accelerating Growth: Unable to compare IGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IGX is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (7.2%).
Return on Equity
High ROE: IGX has a negative Return on Equity (-262.8%), as it is currently unprofitable.